AAD 2026Abstract 75192
Beyond skin clearance
Tildrakizumab improves high burdensome symptoms and psychological well-being in moderate-to-severe psoriasis patients – 2-year POSITIVE study results
Mrowietz U, Sommer R, Reguiai Z, Daudén E, Maul JT, Naldi L, de Jong E, Koscielny V, Massana E, Kasujee I, Augustin M
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: PsoriasisPsychodermatologyBiologics
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.311 · Not in PubMed: details from Crossref